For research use only. Not for therapeutic Use.
Firazorexton hydrate(CAT: I040952) is a potent, brain-penetrant, and orally active agonist of the orexin type 2 receptor (OX2R), with an EC50 of 19 nM. By targeting the OX2R, Firazorexton hydrate effectively modulates the orexin system, playing a critical role in the regulation of wakefulness. In preclinical studies, it has demonstrated efficacy in inhibiting fragmentation of wakefulness and cataplexy-like episodes in mouse models of narcolepsy. This makes Firazorexton hydrate a promising candidate for Neurological Disease Research, particularly for advancing treatments for narcolepsy and related sleep disorders.
| CAS Number | 2861934-86-1 |
| Molecular Formula | C44H56F6N4O11S2 |
| Purity | ≥95% |
| IUPAC Name | N-[(2S,3S)-2-[[3-(3,5-difluorophenyl)-2-fluorophenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]methanesulfonamide;trihydrate |
| InChI | InChI=1S/2C22H25F3N2O4S.3H2O/c2*1-22(2,29)21(28)27-8-7-18(26-32(3,30)31)19(27)11-13-5-4-6-17(20(13)25)14-9-15(23)12-16(24)10-14;;;/h2*4-6,9-10,12,18-19,26,29H,7-8,11H2,1-3H3;3*1H2/t2*18-,19-;;;/m00.../s1 |
| InChIKey | XNRBNIWRMZALLM-JRMNKBLGSA-N |
| SMILES | CC(C)(C(=O)N1CC[C@@H]([C@@H]1CC2=C(C(=CC=C2)C3=CC(=CC(=C3)F)F)F)NS(=O)(=O)C)O.CC(C)(C(=O)N1CC[C@@H]([C@@H]1CC2=C(C(=CC=C2)C3=CC(=CC(=C3)F)F)F)NS(=O)(=O)C)O.O.O.O |
